Background Epidermolysis bullosa simplex generalized severe (EBS-gen sev) is a genetic disorder caused by mutation in the KRT5 or KRT14 genes. Although it is usually considered a mechanical disease, recent data argue for additional inflammatory mechanisms. Objectives To assess the inflammation in the skin of patients with EBS-gen sev. Methods A first immunohistochemical retrospective study was performed on frozen skin samples from 17 patients with EBS-gen sev. A second multicentre prospective study was conducted on 10 patients with severe EBS-gen sev. Blister fluid and epidermis were processed for immunochemical analysis and quantitative real-time polymerase chain reaction. Cytokine expression was analysed in blister fluid and compared with that in controls. Results Histological analysis showed a constant dermal perivascular CD4 + lympho-
What does this study add?
• We showed the presence of an immune infiltrate characterized by a T helper (Th) 17 phenotype in the skin of patients with EBS-gen sev.
• There was a marked improvement of the skin condition in patients with EBS after treatment with apremilast, an anti-Th17 molecule.
What is the translational message?
• Our results demonstrate the importance of inflammation in EBS-gen sev and underline the key role of Th17 activation.
• Anti-Th17 molecules such as apremilast provide a promising new therapeutic approach for this disabling disorder.
Epidermolysis bullosa is a group of hereditary disorders characterized by skin and mucosal fragility resulting in post-traumatic blistering. 1 In epidermolysis bullosa simplex generalized severe (EBS-gen sev), blisters are present at birth, have a herpetiform pattern 2 and involve the mucosa.
Progressive improvement with age is common, but there is increased neonatal mortality due to development of severe infections. 3 The disease results from mutations affecting either keratin 14 or keratin 5, which are type I and type II intermediate filament proteins, respectively, expressed in basal keratinocytes in the epidermis. 4 EBS-gen sev was initially considered to be a mechanical disease due to the fragility of the patients' keratinocytes. 5 However, this theory fails to explain all the clinical features of the disease, and recent studies have suggested that additional inflammatory mechanisms may be involved. [6] [7] [8] [9] [10] [11] The latter hypothesis is supported by growing evidence for distinct regulatory functions of keratins in skin immunity and inflammation, [12] [13] [14] [15] and encouraging results of topical anti-inflammatory treatments. 16 We have shown, for the first time, the presence of an immune infiltrate characterized by a T helper (Th)17 phenotype in the skin of patients with EB-gen sev, and a marked improvement of the skin condition in patients with EBS-gen sev after the use of apremilast, an anti-Th17 molecule, suggesting a promising new treatment for this disabling disorder.
Materials and methods
The aim of this study was to analyse the skin inflammation associated with EBS-gen sev. Our study consisted of two parts: firstly, an immunohistochemical retrospective study using frozen skin samples, and secondly, a multicentre prospective study. Molecular analysis was performed by the Scottish Molecular Genetic Consortium at Dundee University as previously described. 17 
Patients
Retrospective study
All patients with EBS-gen sev who had skin biopsies at the edge of a noninfected blister taken between 1996 and 2012 for diagnosis, and whose tissue was stored at À80°C, were enrolled following their written consent. Diagnosis of EBS-gen sev was established on the association of clinical and immunohistological criteria.
Prospective study
Patients of either sex, older than 1 year of age, who were diagnosed with EBS-gen sev and who developed more than two new blisters per day were eligible for this study. Six French centres participated during the period of March to October 2012. All procedures were approved by the human ethics committees. Informed consent was obtained from all patients. In each centre, following dermatological examination of the patient, the investigators filled in a standardized questionnaire and obtained the following biological samples: (i) liquid content of at least three blisters (pooled in the same dry tube) and (ii) two blister roofs (one fixed in formalin for immunohistochemistry and one in RNAlater for RNA extraction).
Controls
Samples were obtained from four healthy volunteers, in whom blisters were induced by mechanical suction of the skin.
Therapeutic pilot study
Following the promising results seen with the initial biological data obtained, we proposed to three adult patients with EBSgen sev with disabling generalized blistering that they start treatment with apremilast.
Histological and immunohistochemical analysis
For the retrospective study, most skin samples were frozen. For the prospective study, the roofs of blisters had been conserved in Tissue-Tek â (Sakura Finetek, Torrance, CA, U.S.A.) and stored at À80°C. Skin sections were prepared and stained with haematoxylin-phloxine-saffron (HPS) (to assess the cellular infiltrate) and immunolabelled for CD4 and CD8 T cells or CXCL9 and CXCL10. Details of the technique are available in Appendix S1 (see Supporting Information).
Analysis of gene expression in the blister roofs, RNA extraction and reverse-transcriptase polymerase chain reaction After fixation of blister roofs in RNAlater for 24 h at 4°C, total RNA was extracted using RNeasy extraction kits (Qiagen, Venlo, the Netherlands) according to the manufacturer's protocol. RNA quantity was measured using a Nanodrop Spectrophotometer ND8000 (Thermo Fisher Scientific, Waltham, MA, U.S.A.). cDNA was prepared by reverse transcription with oligo-dT using the Omniscript RT Kit (Qiagen) and was used as a template for amplification by polymerase chain reaction with specific primers directed against Th1, Th2 and Th17 cytokine genes. mRNA was expressed as the relative quantity above the housekeeping gene control.
Cytokine analysis in the blister fluid
The blister fluids were stored at 4°C and sent to the lab within 24 h. Liquids were centrifuged at 2000 r.p.m. for 10 min at 4°C (value in g unavailable). The supernatants were collected and frozen at À80°C. Immunoassays based on Luminex TM xMAP TM technology for multianalyte profiling (Luminex, Austin, TX, U.S.A.) were carried out on the blister fluid for detection and quantitation of cytokines.
Results
Patients with epidermolysis bullosa simplex generalized severe have clinical hallmarks of inflammatory skin disease Seventeen patients with EBS-gen sev were included in the retrospective study and 10 in the prospective study. Five patients participated in both arms of the study. Their clinical and biological features are summarized in Table 1 .
All patients had flare-ups of their disease and complained of spontaneous and unexplained flare-ups. Interestingly, inflammatory or general factors such as cutaneous infection (seven of 10), vaccines (two), tooth eruption (four) and fever (three) were reported to induce blisters, whereas improvement was induced by protecting the skin from friction and cold, application of topical steroids (four of 10), fever (three) and use of local or systemic antibiotics (seven). The blisters were often preceded by erythema, suggesting a pre-existing local inflammation (eight of 10), and in those cases some patients reported that topical application of steroids could prevent the onset of blisters.
The mean duration of wound healing ranged from a few days (four of 10 patients) to 2 weeks (three patients). The majority of patients (eight of 10) reported the development of nonhealing blisters over friction areas, with chronic extensive blisters. Emollient creams or petrolatum cream (six of 10) and also topical antibiotics (seven of 10) were reported to be effective by patients, even without clinical infection.
Patients with epidermolysis bullosa simplex generalized severe have a perivascular dermal CD4 + lymphocytic infiltrate in blistering and rubbed skin Twenty-two frozen skin biopsies were analysed in the retrospective study. Among the 17 patients included, five also had a skin biopsy taken from rubbed, normal-looking skin. Examination of the HPS-stained sections showed a dermal inflammatory infiltrate in all biopsies (Fig. 1a) . This infiltrate was always localized in the superficial dermis with a perivascular distribution; it was sparse (+) in 11 biopsies, moderate (++) in nine and dense (+++) in two. Infiltrating cells were predominantly lymphocytic; neutrophils were detected in only two patients and eosinophils in one patient.
Immunohistochemical staining for T-cell antigens showed that the inflammatory infiltrate consisted mainly of CD3 + T lymphocytes (Fig. 1b) . Analysis of the lymphocytic subsets of CD4 and CD8 T cells (Fig. 1c, d) showed that the infiltrate was composed mainly of CD4 + lymphocytes (19 of 21 cases) (Fig. 1c) . There was no difference in the type or degree of immune infiltrate according to the mutational profile (KRT5 vs. KRT14). Interestingly, analysis of biopsies taken from rubbed skin showed similar results ( Fig. S1 ; see Supporting Information).
Infiltration with eosinophils and neutrophils can be present in lesional skin
For five patients from the retrospective study, histological analysis of a nonfrozen skin biopsy of a blister was possible (Fig. 2 ). An eosinophilic infiltrate was present in four of these patients in the dermis (four) and/or the epidermis (two). These eosinophils were not visible on the frozen sections, suggesting the limitation of this technique. The prospective study included 10 roof blisters. Immunochemistry showed necrosis of the epidermis in all patients. Six patients had a dense epidermal neutrophilic infiltrate, with eosinophils in two cases. In two patients the infiltrate was made only of eosinophils. Two patients had no inflammatory cells in the epidermis. controls. The levels of interleukin (IL)-8, a neutrophil chemoattractant produced by keratinocytes and macrophages, were elevated in all patients (six of six), as were markers of Th17 immune response, including IL-17 (six), IL-21 (six) and IL-22 (four), which were significantly elevated compared with controls ( Fig. 3) .
The levels of Th1 [interferon (IFN)-c and tumour necrosis factor alpha (TNF)-a] and Th2 cytokines (IL-4 and IL-5) remained unchanged; however, T-regulatory cytokines [IL-10 and transforming growth factor (TGF)-b]
were elevated above baseline in four and six out of six patients, respectively (Fig. 3) . The cytokine protein content of the blister fluid was analysed in eight patients with EBS-gen sev and was compared with that in the blister fluid from four healthy controls. We found significantly increased levels of TNF-a and CCL20 (two inflammatory cytokines), IL-5 (a Th2 cytokine) and IL-22 (Fig. 4) . Other Th2 cytokines, such as IL-4 and IL-13, remained unchanged. The levels of the Th1 cytokines IFN-c, IL-6 and IL-1b were increased, but the difference failed to reach statistical significance ( Fig. S2 ; see Supporting Information).
Finally, analysis of Th17 cytokines at the protein level supported the data obtained at the mRNA level, which showed increased levels of IL-17A, IL-17F, IL-21 and IL-22 (Fig. 4) . Taken together, these results argue for the role of inflammation, and especially inflammation mediated by Th17 cells, in the pathogenesis of EBS-gen sev.
Blistering skin of patients with epidermolysis bullosa simplex generalized severe overexpresses CXCL9 and CXCL10
Keratinocytes are potent attractants for immune cells as they secrete large amounts of chemokines. 18, 19 We thus hypothesized that increased production of chemokines in EBS-gen sev skin could be the initiating event for the immune infiltrate. Using EBS-gen sev skin from four children with the disease and four skin samples from healthy controls, we found significantly increased numbers of CXCL9-and CXCL10-immunopositive cells in EBS-gen sev skin compared with controls (Fig. 5) .
Treatment of patients with epidermolysis bullosa simplex generalized severe with apremilast improves cutaneous symptoms
Based on these data, we initiated treatment with apremilast in three adult patients (three women aged 33-55 years) with EBS-gen sev. Apremilast is a small molecule that specifically inhibits cyclic AMP phosphodiesterase-4 and Th1/Th17 activation, and has been approved for the treatment of psoriasis. 20, 21 Patients 1 and 2 in this substudy were a mother and her daughter with KRT5 mutation, and the mutational status was unknown for patient 3. Before treatment, all patients had at least four or five body zones with chronic active blistering, despite protective measures and topical treatments (Fig. 6a, c, e) . The patients started apremilast according to the psoriasis regimen (progressive dose increase from 10 mg daily to 30 mg twice daily) 20 in spring or summer. After 10, 15 and 30 days, respectively, a dramatic decrease in the number of blisters was observed (Fig. 6b, d, f) . The three patients initially complained of mild abdominal pain and diarrhoea, which progressively disappeared within 1 month. Patient 3 complained of persistent nausea and stopped the treatment after 7 months. No other adverse events were reported. There was no recurrence after 10 and 8 months of treatment for patients 1 and 2, respectively. Patient 3 had recurrence of blistering 2 days after the discontinuation of apremilast.
Discussion
In our study we confirm that patients with EBS-gen sev have clinical hallmarks of an inflammatory skin disease. Furthermore, patients have a dermal infiltrate of CD3 + CD4 + lymphocytes in lesional (and to a lesser extent nonlesional) skin and epidermal necrosis, suggesting a role for cell-mediated immunity. These results are in accordance with the literature. 10, 11 Keratinocytes are the main cells producing CXCL9, CXCL10 and CCL20, three potent attractors of lymphocytes in the skin of patients with several autoimmune skin diseases or in the early phases of wound healing. 18, 22, 23 Consistently with these results we found increased expression of CXCL9 and CXCL10 in lesional skin compared with control skin, and an increased level of CCL20 in the blister fluid of patients with EBS-gen sev, suggesting that these chemokines are likely to play an important role in the lymphocytic infiltrate. Upregulation of CCL2 and CCL20 has already been shown in the skin of keratin 5 À/À mice, but not in keratin 14 À/À mice. 6 In our study, the levels of CCL20 were not related to the mutational status of the patients. To try to understand what type of inflammation was induced by the cutaneous CD4 + T cells, we analysed the liquid and the roof of the blisters, and found increased levels of IL-8, IL-1b and IL-5 and an abundance of Th17 cytokines, at both the mRNA and protein levels. Unfortunately, due to the very small amount of material available and the small number of patients, we were not able to explore the expression of all cytokines. Increased levels of IL-1b and IL-8 have previously been shown in vitro and in the skin of patients with EBS. 7, 8, 24 It has been shown previously that in the early stages of wound healing, keratinocytes become 'activated' and release inflammatory molecules such as IL-1 and IL-8 (to initiate innate immunity and subsequent neutrophil recruitment), and also CCL20 (to recruit monocytes or myeloid dendritic cells and T cells into a focal skin region). 18 Taken together, these data suggest that the increase in IL-1 and IL-8 is not specific to EBS, but is more likely to be induced by the wound; this can partially explain the granulocytic infiltrate observed in the lesional skin. The increased expression of IL-5, at both the mRNA level on the blister roof and at the protein level by enzyme-linked immunosorbent assay in the blister fluid, is an intriguing finding. IL-5 is a Th2 cytokine and a key mediator in eosinophil maturation, activation and recruitment. Its elevated level in the skin of patients with EBS is in accordance with the presence of eosinophils in these patients' skin. Surprisingly, other Th2 cytokines such as IL-4 and IL-13 were not increased in our patients, suggesting that IgE may not play a crucial role in the development and/or progress of this disease. The reason for this increase is not known; however, IL-5 and eosinophils are involved in the physiopathology of bullous pemphigoid, an autoimmune blistering disease of the skin, suggesting that these data are not causal. 25 Here we show, for the first time, that epidermolysis bullosa is characterized by an increase in cytokines inducing the differentiation of T cells into Th17 cells, such as TGF-b, IL-6 and IL-21, high levels of Th17 effector cytokines such as IL-17, IL-21 and IL-22, and low levels of cytokines inhibiting Th17 differentiation, such as IFN-c and IL-4. These data strongly suggest the involvement of the Th17 immune response in the pathogenesis of EBS-gen sev. Th17 cells play a role in adaptive immunity protecting the body against pathogens via the production of antimicrobial peptides, recruitment of immunocytes via induction of chemokines such as CCL20, and tissue repair by enhancing epithelial proliferation. 26 The Th17 signalling pathway is tightly controlled and is terminated after infection is ablated and tissue repair completed. However, Th17 signalling is persistently activated in inflammatory or genetic diseases such as psoriasis, 27 rheumatoid arthritis and ichthyosis. 28 In psoriasis, Th17 cells are recruited by CCL20; this chemokine is released from keratinocytes by Th17 cytokines, highlighting the critical role of CCL20 in Th17 activation and psoriasis pathogenesis. In EBS-gen sev, mutation of KRT5 and KRT14 can lead to a 'stressed' phenotype of keratinocytes with uncontrolled Th17 activation by infection or physical or chemical stress. Based on these results, we examined the effect of apremilast, an approved treatment used in psoriasis, in patients with EBS-gen sev. 29 In the three treated patients, apremilast achieved a rapid and sustained improvement. A limitation of this pilot therapeutic study is the limited number of patients treated and the absence of objective assessment of improvement; however, these patients were the most severely affected adult patients, who had active diffuse blisters despite topical treatment. The sustained improvement for up to 7-10 months of follow-up supports the value of this therapeutic approach. According to our results, anti-IL-17 antibodies could also be of interest for treating patients with EBS-gen sev. Taken together, our results demonstrate the importance of inflammation in EBS-gen sev and underline the key role of Th17 activation. They also provide a promising new therapeutic approach for this disabling disorder.
